IDNAPTEX BRAF-CNS

Set of probes and primers for the detection
of BRAF mutation and Exon 14 duplication

Optimized for

QIAcuity^® Digital PCR system

Product description

IDNAPTEX BRAF-CNS reliably detects mutations in the BRAF gene. It uses an optimised mix of primers and fluorescent probes.

IDNAPTEX BRAF-CNS targets the Exon 15 mutation (V600E) as well as duplications of Exons 9, 10 and 11 up to 18, via Exon 14 (KIAA1549-BRA fusion).

ICE* technology ensures optimal sensitivity and reproducibility. Developed by ID SOLUTIONS, it is essential for the analysis of plasma (cfDNA) or FFPE tissue (gDNA) samples.

The reagents are supplied in pre-mixed tubes. The primers and probes are ready-to-use to simplify preparation. This configuration improves the reproducibility of results.

Ready to use

gDNA & cfDNA

ID SOLUTIONS’ patented* technology

The ICE control has been implemented specifically to validate the extraction procedure for each sample tested.

Features

Content

4 tubes of PRIMEX BRAF-CNS primers and probes – 24 reactions each
2 tubes of TPC BRAF-CNS target process controls – 10 reactions each

Sample

Circulating free DNA (cfDNA) extracted from a plasma sample

Genomic DNA (gDNA) Isolated form formalin-fixed, paraffin-embedded tissue (FFPE)

Targets

Exon 15: V600E
Exon 9 / 10 / 11 to 18: Duplication via Exon 14 (fusion of KIAA1549-BRAF)

Controls

Target Positive Control (TPC) included in the kit DIgestion Control Efficiency (DICE)

Turnaround time

24 samples: < 3h (DNA to product)

Platform

QIAcuity^® 5Plex dPCR system
QIAcuity^® Probe PCR kit
QIAcuity^® Nanoplate 26K

Storage T°C

-20°C

Reference

1141-011116-96

Associated products

ID-ICE (ref. 1171-000000-96)

*ID-ICE can be ordered separately. The patented ID SOLUTIONS technology is protected in Europe by patent number EP 3565902 and in the United States by patent number 12049664.

QIAcuity is a registered trademark of QIAGEN. QIAcuity dPCR instruments, consumables and tests are sold by QIAGEN under licence from Bio-Rad Laboratories, Inc. for use on QIAcuity Digital PCR instruments and exclude rights for use in paediatric applications.

QIAcuity is intended for molecular biology applications. This product is not intended for use in the diagnosis, prevention, or treatment of disease. Therefore, the performance characteristics of the product for clinical use (i.e., diagnostic, prognostic, therapeutic, or blood banking) are unknown.

Trademarks: QIAGEN®, QIAcuity®. Registered names, trademarks, etc. used in this document, even if not specifically marked as such, may be protected by law.

ID SOLUTIONS and IDNAPTEX are registered trademarks of ID SOLUTIONS.

Produits associés

IDXtract

IDXTRACT-50

IDXtract-MAG

IDXTRACT-MAG-24/100

IDXtract-MAG-FFPE

IDXTRACT-MAG-FFPE-96/384